Fang Wei

Title: Fang Wei: Innovator in Oncogenic Research

Introduction

Fang Wei is a prominent inventor based in Drexel Hill, PA (US). She has made significant contributions to the field of oncology through her innovative research and patents. With a focus on transforming normal human cells, her work has the potential to impact cancer treatment and understanding.

Latest Patents

Fang Wei holds a patent for her invention titled "Anaplastic lymphoma kinase (ALK) as an oncogene capable of transforming normal human cells." This invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of ALK. The transformed cells exhibit features similar to those of tumor cells isolated from cancer subjects. Additionally, her invention includes a method for immortalizing normal CD4+ T lymphocytes with a lymphoma-characteristic form of ALK, such as NPM-ALK. She has 1 patent to her name.

Career Highlights

Fang Wei is affiliated with the University of Pennsylvania, where she conducts her research and develops her innovative ideas. Her work is recognized for its potential to advance the understanding of cancer biology and therapeutic approaches.

Collaborations

Fang Wei collaborates with esteemed colleagues, including Mariusz Wasik and James L. Riley. These partnerships enhance her research and contribute to the advancement of knowledge in the field of oncology.

Conclusion

Fang Wei's contributions to oncogenic research through her innovative patent highlight her role as a leading inventor in the field. Her work not only furthers scientific understanding but also holds promise for future cancer therapies.